{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:15:14Z","timestamp":1790864114611,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2010,9,8]],"date-time":"2010-09-08T00:00:00Z","timestamp":1283904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1038\/npp.2010.133","type":"journal-article","created":{"date-parts":[[2010,9,9]],"date-time":"2010-09-09T06:54:26Z","timestamp":1284015266000},"page":"2564-2578","source":"Crossref","is-referenced-by-count":23,"title":["Is Slow-Onset Long-Acting Monoamine Transport Blockade to Cocaine as Methadone is to Heroin? Implication for Anti-Addiction Medications"],"prefix":"10.1038","volume":"35","author":[{"given":"Xiao-Qing","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Xiong","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Spiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Ming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Froimowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliot L","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,8]]},"reference":[{"key":"BFnpp2010133_CR1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/00008877-199000140-00009","volume":"1","author":"J Bergman","year":"1990","unstructured":"Bergman J, Kamien JB, Spealman RD (1990). Antagonism of cocaine self-administration by selective dopamine D1 and D2 antagonists. Behav Pharmacol 1: 355\u2013363.","journal-title":"Behav Pharmacol"},{"key":"BFnpp2010133_CR2","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1124\/mol.106.027763","volume":"71","author":"EA Bolan","year":"2007","unstructured":"Bolan EA, Kivell B, Jaligam V, Oz M, Jayanthi LD, Han Y et al (2007). D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Mol Pharmacol 71: 1222\u20131232.","journal-title":"Mol Pharmacol"},{"key":"BFnpp2010133_CR3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2165\/00003088-198611020-00004","volume":"11","author":"U Busto","year":"1986","unstructured":"Busto U, Sellers EM (1986). Pharmacokinetic determinants of drug abuse and dependence. A conceptual perspective. Clin Pharmacokinet 11: 144\u2013153.","journal-title":"Clin Pharmacokinet"},{"key":"BFnpp2010133_CR4","doi-asserted-by":"publisher","first-page":"E196","DOI":"10.1208\/aapsj080124","volume":"8","author":"FI Carroll","year":"2006","unstructured":"Carroll FI, Howard JL, Howell LL, Fox BS, Kuhar MJ (2006). Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse. AAPS J 8: E196\u2013E203.","journal-title":"AAPS J"},{"key":"BFnpp2010133_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1471-4159.2006.04384.x","volume":"101","author":"N Chen","year":"2007","unstructured":"Chen N, Reith MEA (2007). Substrates and inhibitors display different sensitivity to expression level of the dopamine transporter in heterologously expressing cells. J Neurochem 101: 377\u2013388.","journal-title":"J Neurochem"},{"key":"BFnpp2010133_CR6","doi-asserted-by":"publisher","first-page":"9333","DOI":"10.1073\/pnas.0600905103","volume":"103","author":"R Chen","year":"2006","unstructured":"Chen R, Tilley MR, Wei H, Zhou F, Zhou F-M, Ching S et al (2006). Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter. Proc Natl Acad Sci USA 103: 9333\u20139338.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFnpp2010133_CR7","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1124\/jpet.103.055095","volume":"307","author":"L Chi","year":"2003","unstructured":"Chi L, Reith MEA (2003). Substrate-induced trafficking of the dopamine transporter in heterologously expressing cells and in rat striatal synaptosomal preparations. J Pharmacol Exp Ther 307: 729\u2013736.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFnpp2010133_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1192\/bjp.bp.107.041228","volume":"193","author":"MR Daglish","year":"2008","unstructured":"Daglish MR, Williams TM, Wilson SJ, Taylor LG, Eap CB, Augsburger M et al (2008). Brain dopamine response in human opioid addiction. Br J Psychiatry 193: 65\u201372.","journal-title":"Br J Psychiatry"},{"key":"BFnpp2010133_CR9","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1006\/bbrc.2002.6384","volume":"290","author":"LC Daws","year":"2002","unstructured":"Daws LC, Callaghan PD, Mor\u00f3n JA, Kahlig KM, Shippenberg TS, Javitch JA et al (2002). Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochem Biophys Res Commun 290: 1545\u20131550.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFnpp2010133_CR10","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1523\/JNEUROSCI.4778-04.2005","volume":"25","author":"RI Desai","year":"2005","unstructured":"Desai RI, Kopajtic TA, Koffarnus M, Newman AH, Katz JL (2005). Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J Neurosci 25: 1889\u20131893.","journal-title":"J Neurosci"},{"key":"BFnpp2010133_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0376-8716(95)01118-I","volume":"38","author":"G Di Chiara","year":"1995","unstructured":"Di Chiara G (1995). The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend 38: 95\u2013137.","journal-title":"Drug Alcohol Depend"},{"key":"BFnpp2010133_CR12","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1001\/jama.1965.03090080008002","volume":"193","author":"VP Dole","year":"1965","unstructured":"Dole VP, Nyswander ME (1965). A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. JAMA 193: 646\u2013650.","journal-title":"JAMA"},{"key":"BFnpp2010133_CR13","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1001\/archinte.1966.00290160004002","volume":"118","author":"VP Dole","year":"1966","unstructured":"Dole VP, Nyswander ME, Kreek MJ (1966). Narcotic blockade. Arch Intern Med 118: 304\u2013309.","journal-title":"Arch Intern Med"},{"key":"BFnpp2010133_CR14","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1111\/j.1360-0443.2005.01232.x","volume":"100","author":"EC Donny","year":"2005","unstructured":"Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL (2005). Methadone doses of 100\u2009mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction 100: 1496\u20131509.","journal-title":"Addiction"},{"key":"BFnpp2010133_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00213-002-1027-0","volume":"161","author":"EC Donny","year":"2002","unstructured":"Donny EC, Walsh SL, Bigelow GE, Eissenberg T, Stitzer ML (2002). High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology 161: 202\u2013212.","journal-title":"Psychopharmacology"},{"key":"BFnpp2010133_CR16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00213-009-1653-x","volume":"207","author":"A Ferragud","year":"2009","unstructured":"Ferragud A, Vel\u00e1zquez-S\u00e1nchez C, Hern\u00e1ndez-Rabaza V, N\u00e1cher A, Merino V, Card\u00e1 M et al (2009). A dopamine transport inhibitor with markedly low abuse liability suppresses cocaine self-administration in the rat. Psychopharmacology 207: 281\u2013289.","journal-title":"Psychopharmacology"},{"key":"BFnpp2010133_CR17","volume-title":"Treating Tabacco Use and Dependence\u2014Clinical Practice Guideline: 2008 Update (Agency for Health Care Research and Quality [AHRQ] Publication No. 08-0050-1)","author":"MC Fiore","year":"2008","unstructured":"Fiore MC, Ja\u00e9n CR, Baker TB, Bailey WC, Benowitz NL et al (2008). Treating Tabacco Use and Dependence\u2014Clinical Practice Guideline: 2008 Update (Agency for Health Care Research and Quality [AHRQ] Publication No. 08-0050-1). United States Department of Health and Human Services (U.S. Public Health Service): Rockville, Maryland."},{"key":"BFnpp2010133_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1021\/jm0608614","volume":"50","author":"M Froimowitz","year":"2007","unstructured":"Froimowitz M, Gu Y, Dakin LA, Nagafuji PM, Kelley CJ, Parrish D et al (2007). Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem 50: 219\u2013232.","journal-title":"J Med Chem"},{"key":"BFnpp2010133_CR19","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1021\/jm000201d","volume":"43","author":"M Froimowitz","year":"2000","unstructured":"Froimowitz M, Wu K-M, Moussa A, Haidar RM, Jurayj J, George C et al (2000). Slow-onset, long-duration 3-(3\u2032,4\u2032-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse. J Med Chem 43: 4981\u20134992.","journal-title":"J Med Chem"},{"key":"BFnpp2010133_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/105504900750047355","volume":"9","author":"EL Gardner","year":"2000","unstructured":"Gardner EL (2000). What we have learned about addiction from animal models of drug self-administration. Am J Addict 9: 285\u2013313.","journal-title":"Am J Addict"},{"key":"BFnpp2010133_CR21","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.neuropharm.2006.06.009","volume":"51","author":"EL Gardner","year":"2006","unstructured":"Gardner EL, Liu X, Paredes W, Giordano A, Spector J, Lepore M et al (2006). A slow-onset, long-duration indanamine monoamine reuptake inhibitor as a potential maintenance pharmacotherapy for psychostimulant abuse: effects in laboratory rat models relating to addiction. Neuropharmacology 51: 993\u20131003.","journal-title":"Neuropharmacology"},{"key":"BFnpp2010133_CR22","doi-asserted-by":"publisher","first-page":"4689","DOI":"10.1021\/jm960551t","volume":"39","author":"JR Glowa","year":"1996","unstructured":"Glowa JR, Fantegrossi WE, Lewis DB, Matecka D, Rice KC, Rothman RB (1996). Sustained decrease in cocaine-maintained responding in rhesus monkeys with 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-hydroxy-3-phenylpropyl) piperazinyl decanoate, a long-acting ester derivative of GBR 12909. J Med Chem 39: 4689\u20134691.","journal-title":"J Med Chem"},{"key":"BFnpp2010133_CR23","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.addbeh.2004.06.018","volume":"29","author":"J Grabowski","year":"2004","unstructured":"Grabowski J, Shearer J, Merrill J, Negus SS (2004). Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav 29: 1439\u20131464.","journal-title":"Addict Behav"},{"key":"BFnpp2010133_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(24)29344-7","volume":"298","author":"LL Howell","year":"2001","unstructured":"Howell LL, Wilcox KM (2001). The dopamine transporter and cocaine medication development: drug self-administration in nonhuman primates. J Pharmacol Exp Ther 298: 1\u20136.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFnpp2010133_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/BF00426764","volume":"54","author":"BE Jones","year":"1977","unstructured":"Jones BE, Prada JA (1977). Effects of methadone and morphine maintenance on drug-seeking behavior in the dog. Psychopharmacology 54: 109\u2013112.","journal-title":"Psychopharmacology"},{"key":"BFnpp2010133_CR26","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1124\/mol.106.023952","volume":"70","author":"KM Kahlig","year":"2006","unstructured":"Kahlig KM, Lute BJ, Wei Y, Loland CJ, Gether U, Javitch JA et al (2006). Regulation of dopamine transporter trafficking by intracellular amphetamine. Mol Pharmacol 70: 542\u2013548.","journal-title":"Mol Pharmacol"},{"key":"BFnpp2010133_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1124\/mol.53.3.377","volume":"53","author":"DE Keith","year":"1998","unstructured":"Keith DE, Anton B, Murray SR, Zaki PA, Chu PC, Lissin DV et al (1998). \u03bc-Opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Mol Pharmacol 53: 377\u2013384.","journal-title":"Mol Pharmacol"},{"key":"BFnpp2010133_CR28","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.neubiorev.2003.11.007","volume":"27","author":"GF Koob","year":"2004","unstructured":"Koob GF, Ahmed SH, Boutrel B, Chen SA, Kenny PJ, Markou A et al (2004). Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev 27: 739\u2013749.","journal-title":"Neurosci Biobehav Rev"},{"key":"BFnpp2010133_CR29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0304-3940(87)90451-4","volume":"79","author":"GF Koob","year":"1987","unstructured":"Koob GF, Le HT, Creese I (1987). The D1 dopamine receptor antagonist SCH 23390 increases cocaine self-administration in the rat. Neurosci Lett 79: 315\u2013320.","journal-title":"Neurosci Lett"},{"key":"BFnpp2010133_CR30","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1016\/j.addbeh.2007.01.030","volume":"32","author":"LT Kozlowski","year":"2007","unstructured":"Kozlowski LT, Giovino GA, Edwards B, Difranza J, Foulds J, Hurt R et al (2007). Advice on using over-the-counter nicotine replacement therapy-patch, gum, or lozenge-to quit smoking. Addict Behav 32: 2140\u20132150.","journal-title":"Addict Behav"},{"key":"BFnpp2010133_CR31","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1046\/j.1471-4159.1999.0720585.x","volume":"72","author":"HK Kramer","year":"1999","unstructured":"Kramer HK, Simon EJ (1999). Role of protein kinase C (PKC) in agonist-induced \u03bc-opioid receptor down-regulation: I. PKC translocation to the membrane of SH-SY5Y neuroblastoma cells is induced by \u03bc-opioid agonists. J Neurochem 72: 585\u2013593.","journal-title":"J Neurochem"},{"key":"BFnpp2010133_CR32","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1749-6632.2000.tb06683.x","volume":"909","author":"MJ Kreek","year":"2000","unstructured":"Kreek MJ (2000). Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann NY Acad Sci 909: 186\u2013216.","journal-title":"Ann NY Acad Sci"},{"key":"BFnpp2010133_CR33","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/0165-6147(96)10024-9","volume":"17","author":"MJ Kuhar","year":"1996","unstructured":"Kuhar MJ, Pilotte NS (1996). Neurochemical changes in cocaine withdrawal. Trends Pharmacol Sci 17: 260\u2013264.","journal-title":"Trends Pharmacol Sci"},{"key":"BFnpp2010133_CR34","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/0091-3057(92)90362-J","volume":"41","author":"M Lepore","year":"1992","unstructured":"Lepore M, Franklin KBJ (1992). Modeling drug kinetics with brain stimulation: dopamine antagonists increase self-stimulation. Pharmacol Biochem Behav 41: 489\u2013496.","journal-title":"Pharmacol Biochem Behav"},{"key":"BFnpp2010133_CR35","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1038\/sj.npp.1300435","volume":"29","author":"F Leri","year":"2004","unstructured":"Leri F, Tremblay A, Sorge RE, Stewart J (2004). Methadone maintenance reduces heroin- and cocaine-induced relapse without affecting stress-induced relapse in a rodent model of poly-drug use. Neuropsychopharmacology 29: 1312\u20131320.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2010133_CR36","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0149-7634(99)00015-9","volume":"23","author":"MG LeSage","year":"1999","unstructured":"LeSage MG, Stafford D, Glowa JR (1999). Preclinical research on cocaine self-administration: environmental determinants and their interaction with pharmacological treatment. Neurosci Biobehav Rev 23: 717\u2013741.","journal-title":"Neurosci Biobehav Rev"},{"key":"BFnpp2010133_CR37","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1124\/mol.61.2.436","volume":"61","author":"KY Little","year":"2002","unstructured":"Little KY, Elmer LW, Zhong H, Scheys JO, Zhang L (2002). Cocaine induction of dopamine transporter trafficking to the plasma membrane. Mol Pharmacol 61: 436\u2013445.","journal-title":"Mol Pharmacol"},{"key":"BFnpp2010133_CR38","doi-asserted-by":"publisher","first-page":"22168","DOI":"10.1074\/jbc.M301845200","volume":"278","author":"MK Loder","year":"2003","unstructured":"Loder MK, Melikian HE (2003). The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell lines. J Biol Chem 278: 22168\u201322174.","journal-title":"J Biol Chem"},{"key":"BFnpp2010133_CR39","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1124\/mol.107.039800","volume":"73","author":"CJ Loland","year":"2008","unstructured":"Loland CJ, Desai RI, Zou M-F, Cao J, Grundt P, Gerstbrein K et al (2008). Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Mol Pharmacol 73: 813\u2013823.","journal-title":"Mol Pharmacol"},{"key":"BFnpp2010133_CR40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1124\/mol.59.1.113","volume":"59","author":"RD Mayfield","year":"2001","unstructured":"Mayfield RD, Zahniser NR (2001). Dopamine D2 receptor regulation of the dopamine transporter expressed in Xenopus laevis oocytes is voltage-independent. Mol Pharmacol 59: 113\u2013121.","journal-title":"Mol Pharmacol"},{"key":"BFnpp2010133_CR41","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/med.10014","volume":"22","author":"AH Newman","year":"2002","unstructured":"Newman AH, Kulkarni S (2002). Probes for the dopamine transporter: new leads toward a cocaine-abuse therapeutic\u2014A focus on analogues of benztropine and rimcazole. Med Res Rev 22: 429\u2013464.","journal-title":"Med Res Rev"},{"key":"BFnpp2010133_CR42","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1126\/science.278.5335.66","volume":"278","author":"CP O\u2019Brien","year":"1997","unstructured":"O\u2019Brien CP (1997). A range of research-based pharmacotherapies for addiction. Science 278: 66\u201370.","journal-title":"Science"},{"key":"BFnpp2010133_CR43","first-page":"13","volume":"120","author":"WH Oldendorf","year":"1992","unstructured":"Oldendorf WH (1992). Some relationships between addiction and drug delivery to the brain. NIDA Res Monogr 120: 13\u201325.","journal-title":"NIDA Res Monogr"},{"key":"BFnpp2010133_CR44","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1124\/mol.62.6.1464","volume":"62","author":"MB Patel","year":"2002","unstructured":"Patel MB, Patel CN, Rajashekara V, Yoburn BC (2002). Opioid agonists differentially regulate \u03bc-opioid receptors and trafficking proteins in vivo. Mol Pharmacol 62: 1464\u20131470.","journal-title":"Mol Pharmacol"},{"key":"BFnpp2010133_CR45","volume-title":"The Rat Brain in Stereotaxic Coordinates","author":"G Paxinos","year":"1998","unstructured":"Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates, 4th edn. Academic Press: Sydney."},{"key":"BFnpp2010133_CR46","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00213-002-1137-8","volume":"163","author":"DM Platt","year":"2002","unstructured":"Platt DM, Rowlett JK, Spealman RD (2002). Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development. Psychopharmacology 163: 265\u2013282.","journal-title":"Psychopharmacology"},{"key":"BFnpp2010133_CR47","doi-asserted-by":"publisher","first-page":"29012","DOI":"10.1074\/jbc.M011785200","volume":"31","author":"MEA Reith","year":"2001","unstructured":"Reith MEA, Berfield JL, Wang LC, Ferrer JV, Javitch JA (2001). The uptake inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter. J Biol Chem 31: 29012\u201329018.","journal-title":"J Biol Chem"},{"key":"BFnpp2010133_CR48","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bcp.2007.08.007","volume":"75","author":"RB Rothman","year":"2008","unstructured":"Rothman RB, Baumann MH, Prisinzano TE, Newman AH (2008). Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. Biochem Pharmacol 75: 2\u201316.","journal-title":"Biochem Pharmacol"},{"key":"BFnpp2010133_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02740680","volume":"11","author":"RB Rothman","year":"1995","unstructured":"Rothman RB, Glowa JR (1995). A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909. Mol Neurobiol 11: 1\u201319.","journal-title":"Mol Neurobiol"},{"key":"BFnpp2010133_CR50","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.2174\/156802606778249775","volume":"6","author":"SP Runyon","year":"2006","unstructured":"Runyon SP, Carroll FI (2006). Dopamine transporter ligands: recent developments and therapeutic potential. Curr Top Med Chem 6: 1825\u20131843.","journal-title":"Curr Top Med Chem"},{"key":"BFnpp2010133_CR51","doi-asserted-by":"publisher","first-page":"6850","DOI":"10.1073\/pnas.110035297","volume":"97","author":"C Saunders","year":"2000","unstructured":"Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME et al (2000). Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci USA 97: 6850\u20136855.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFnpp2010133_CR52","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00213-007-0986-6","volume":"196","author":"K Spiller","year":"2008","unstructured":"Spiller K, Xi Z-X, Peng X-Q, Newman AH, Ashby Jr CR, Heidbreder C et al (2008). The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats. Psychopharmacology 196: 533\u2013542.","journal-title":"Psychopharmacology"},{"key":"BFnpp2010133_CR53","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cpr.2009.10.006","volume":"30","author":"JC Veilleux","year":"2010","unstructured":"Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ (2010). A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev 30: 155\u2013166.","journal-title":"Clin Psychol Rev"},{"key":"BFnpp2010133_CR54","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1001\/archpsyc.1995.03950180042006","volume":"52","author":"ND Volkow","year":"1995","unstructured":"Volkow ND, Ding Y-S, Fowler JS, Wang G-J, Logan J, Gatley JS et al (1995). Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 52: 456\u2013463.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp2010133_CR55","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1021\/jm00377a021","volume":"27","author":"WM Welch","year":"1984","unstructured":"Welch WM, Kraska AR, Sarges R, Koe BK (1984). Nontricyclic antidepressant agents derived from cis- and trans-1-amino-4-aryltetralins. J Med Chem 27: 1508\u20131515.","journal-title":"J Med Chem"},{"key":"BFnpp2010133_CR56","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0959-4388(96)80079-1","volume":"6","author":"RA Wise","year":"1996","unstructured":"Wise RA (1996). Neurobiology of addiction. Curr Opin Neurobiol 6: 243\u2013251.","journal-title":"Curr Opin Neurobiol"},{"key":"BFnpp2010133_CR57","first-page":"683","volume-title":"Neurobiology of Mental Illness","author":"RA Wise","year":"2004","unstructured":"Wise RA, Gardner EL (2004). Animal models of addiction. In: Charney DS, Nestler EJ (eds). Neurobiology of Mental Illness, 2nd edn, Oxford University Press: London. pp 683\u2013697."},{"key":"BFnpp2010133_CR58","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ejphar.2004.01.003","volume":"486","author":"WL Woolverton","year":"2004","unstructured":"Woolverton WL, Wang Z (2004). Relationship between injection duration, transporter occupancy and reinforcing strength of cocaine. Eur J Pharmacol 486: 251\u2013257.","journal-title":"Eur J Pharmacol"},{"key":"BFnpp2010133_CR59","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1111\/j.1460-9568.2005.04159.x","volume":"21","author":"Z-X Xi","year":"2005","unstructured":"Xi Z-X, Gilbert JG, Pak AC, Ashby Jr CR, Heidbreder CA, Gardner EL (2005). Selective dopamine D3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost\u2013variable-payoff fixed-ratio cocaine self-administration in rats. Eur J Neurosci 21: 3427\u20133438.","journal-title":"Eur J Neurosci"},{"key":"BFnpp2010133_CR60","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/j.1471-4159.2009.06478.x","volume":"112","author":"Z-X Xi","year":"2010","unstructured":"Xi Z-X, Li X, Peng X-Q, Li J, Chun L, Gardner EL et al (2010). Inhibition of NAALADase by 2-PMPA attenuates cocaine-induced relapse in rats: a NAAG-mGluR2\/3-mediated mechanism. J Neurochem 112: 564\u2013576.","journal-title":"J Neurochem"},{"key":"BFnpp2010133_CR61","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1038\/sj.npp.1300912","volume":"31","author":"Z-X Xi","year":"2006","unstructured":"Xi Z-X, Newman AH, Gilbert JG, Pak AC, Peng X-Q, Ashby Jr CR et al (2006). The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology 31: 1393\u20131405.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2010133_CR62","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1523\/JNEUROSCI.23-08-03498.2003","volume":"23","author":"Z-X Xi","year":"2003","unstructured":"Xi Z-X, Ramamoorthy S, Shen H, Lake R, Samuvel DJ, Kalivas PW (2003). GABA transmission in the nucleus accumbens is altered after withdrawal from repeated cocaine. J Neurosci 23: 3498\u20133505.","journal-title":"J Neurosci"},{"key":"BFnpp2010133_CR63","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/alcalc\/37.5.485","volume":"37","author":"Z-X Xi","year":"2002","unstructured":"Xi Z-X, Stein EA (2002). GABAergic mechanisms of opiate reinforcement. Alcohol Alcohol 37: 485\u2013494.","journal-title":"Alcohol Alcohol"},{"issue":"Suppl 1","key":"BFnpp2010133_CR64","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.neuropharm.2004.07.010","volume":"47","author":"NR Zahniser","year":"2004","unstructured":"Zahniser NR, Sorkin A (2004). Rapid regulation of the dopamine transporter: role in stimulant addiction? Neuropharmacology 47 (Suppl 1): 80\u201391.","journal-title":"Neuropharmacology"},{"key":"BFnpp2010133_CR65","doi-asserted-by":"publisher","first-page":"35842","DOI":"10.1074\/jbc.M611758200","volume":"282","author":"A Zapata","year":"2007","unstructured":"Zapata A, Kivell B, Han Y, Javitch JA, Bolan EA, Kuraguntla D et al (2007). Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors. J Biol Chem 282: 35842\u201335854.","journal-title":"J Biol Chem"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/npp2010133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2010133","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2010133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T17:22:50Z","timestamp":1740504170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/npp2010133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,8]]},"references-count":65,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["BFnpp2010133"],"URL":"https:\/\/doi.org\/10.1038\/npp.2010.133","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,8]]}}}